{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:43:23Z","timestamp":1786178603205,"version":"build-2736575974"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":219,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic neuroinflammation in response to abnormal protein aggregates has been implicated as a critical mechanism in several neurodegenerative diseases, and the modulation of signaling pathways associated with inflammation is being explored as a potential strategy for new therapeutics. In Alzheimer\u2019s disease (AD), the neuroinflammation hypothesis also starts to influence the landscape of drug discovery in place of the previously regarded amyloid hypothesis. As such, the objective of this review is to compile recent advanced in the discovery of anti-neuroinflammatory compounds developed through chemical synthesis and structural modification, providing an overview of current trends in drug discovery strategies and scaffold redesign for the development of the next-generation of anti-neuroinflammatory therapeutics. It was found that the compounds described in the publications could be categorized into four groups: modification of natural compounds, rational drug design, drug screening approaches, and drug repurposing. While the categorization seems to be similar to drug discoveries in other fields, with the modification of natural compounds accounting for most publications, specific observations could still be made. Namely, the growing interest in the multitarget-directed ligand approach reflects the increasing recognition of AD as a multifactorial disease. Despite this, further research is required to identify additional effective activities or the appropriate combinations besides anti-neuroinflammatory activity. Lastly, this review also gives brief overview regarding physicochemical properties of central nervous system\u2013active agents, of which anti-neuroinflammatory compounds are parts of, and suggests the adoption of in silico prediction models as screening tools before the use of in vitro or in vivo models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                    <jats:p>(Created with the program Inkscape. The brain icon illustration was taken from NIAID NIH BioArt Source (bioart.niaid.nih.gov\/bioart\/60))<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12035-026-06114-1","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:25:16Z","timestamp":1786177516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovery of Anti-Neuroinflammatory Compounds in Alzheimer\u2019s Disease: Current Trends and Future Perspectives"],"prefix":"10.1007","volume":"63","author":[{"given":"Nantaphat","family":"Paelaong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittisak","family":"Sripha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingrak","family":"Boondam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"6114_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9:42. https:\/\/doi.org\/10.1186\/s40035-020-00221-2","journal-title":"Transl Neurodegener"},{"key":"6114_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01486-5","volume":"8","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xiao D, Mao Q, Xia H (2023) Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther 8:1\u201332. https:\/\/doi.org\/10.1038\/s41392-023-01486-5","journal-title":"Signal Transduct Target Ther"},{"key":"6114_CR3","first-page":"1003","volume":"1","author":"D Kempuraj","year":"2016","unstructured":"Kempuraj D, Thangavel R, Natteru P, Selvakumar G, Saeed D, Zahoor H et al (2016) Neuroinflammation induces neurodegeneration. J Neurol Neurosurg Spine 1:1003","journal-title":"J Neurol Neurosurg Spine"},{"key":"6114_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Bosch LVD, Zetterberg H, Holtzman DM, Dewachter I (2023) Hallmarks of neurodegenerative diseases. Cell 186:693\u2013714. https:\/\/doi.org\/10.1016\/j.cell.2022.12.032","journal-title":"Cell"},{"key":"6114_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/ijms23031851","volume":"23","author":"RN Lamptey","year":"2022","unstructured":"Lamptey RN, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J (2022) A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci 23:1851. https:\/\/doi.org\/10.3390\/ijms23031851","journal-title":"Int J Mol Sci"},{"key":"6114_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement (N Y) 4:575\u2013590. https:\/\/doi.org\/10.1016\/j.trci.2018.06.014","journal-title":"Alzheimers Dement (N Y)"},{"key":"6114_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S (2023) Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Sig Transduct Target Ther 8:359. https:\/\/doi.org\/10.1038\/s41392-023-01588-0","journal-title":"Sig Transduct Target Ther"},{"key":"6114_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1146\/annurev-physiol-022516-034406","volume":"79","author":"SA Wolf","year":"2017","unstructured":"Wolf SA, Boddeke HW, Kettenmann H (2017) Microglia in physiology and disease. Annu Rev Physiol 79:619\u2013643. https:\/\/doi.org\/10.1146\/annurev-physiol-022516-034406","journal-title":"Annu Rev Physiol"},{"key":"6114_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.815347","volume":"14","author":"S Guo","year":"2022","unstructured":"Guo S, Wang H, Yin Y (2022) Microglia polarization from M1 to M2 in neurodegenerative diseases. Front Aging Neurosci 14:815347. https:\/\/doi.org\/10.3389\/fnagi.2022.815347","journal-title":"Front Aging Neurosci"},{"key":"6114_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","volume":"53","author":"Y Tang","year":"2016","unstructured":"Tang Y, Le W (2016) Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol 53:1181\u20131194. https:\/\/doi.org\/10.1007\/s12035-014-9070-5","journal-title":"Mol Neurobiol"},{"key":"6114_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1172\/JCI58644","volume":"122","author":"RM Ransohoff","year":"2012","unstructured":"Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system. J Clin Invest 122:1164\u20131171. https:\/\/doi.org\/10.1172\/JCI58644","journal-title":"J Clin Invest"},{"key":"6114_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25020962","volume":"25","author":"S Cicchinelli","year":"2024","unstructured":"Cicchinelli S, Pignataro G, Gemma S, Piccioni A, Picozzi D, Ojetti V et al (2024) PAMPs and DAMPs in sepsis: a review of their molecular features and potential clinical implications. Int J Mol Sci 25:962. https:\/\/doi.org\/10.3390\/ijms25020962","journal-title":"Int J Mol Sci"},{"key":"6114_CR13","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"CK Glass","year":"2010","unstructured":"Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918\u2013934. https:\/\/doi.org\/10.1016\/j.cell.2010.02.016","journal-title":"Cell"},{"key":"6114_CR14","doi-asserted-by":"publisher","unstructured":"Shabab T, Ramin Khanabdali, Moghadamtousi SZ, Kadir HA, Mohan G (2017) Neuroinflammation pathways: a general review. Int J Neurosci 127:624\u201333. https:\/\/doi.org\/10.1080\/00207454.2016.1212854","DOI":"10.1080\/00207454.2016.1212854"},{"key":"6114_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC (2017) NF-\u03baB signaling in inflammation. Signal Transduct Target Ther 2:1\u20139. https:\/\/doi.org\/10.1038\/sigtrans.2017.23","journal-title":"Signal Transduct Target Ther"},{"key":"6114_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.bbadis.2009.12.009","volume":"1802","author":"EK Kim","year":"2010","unstructured":"Kim EK, Choi E-J (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396\u2013405. https:\/\/doi.org\/10.1016\/j.bbadis.2009.12.009","journal-title":"Biochim Biophys Acta"},{"key":"6114_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.113043","volume":"400","author":"M Chen","year":"2021","unstructured":"Chen M, Huang N, Liu J, Huang J, Shi J, Jin F (2021) AMPK: a bridge between diabetes mellitus and Alzheimer\u2019s disease. Behav Brain Res 400:113043. https:\/\/doi.org\/10.1016\/j.bbr.2020.113043","journal-title":"Behav Brain Res"},{"key":"6114_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.biochi.2021.11.008","volume":"195","author":"Y Ge","year":"2022","unstructured":"Ge Y, Zhou M, Chen C, Wu X, Wang X (2022) Role of AMPK mediated pathways in autophagy and aging. Biochimie 195:100\u2013113. https:\/\/doi.org\/10.1016\/j.biochi.2021.11.008","journal-title":"Biochimie"},{"key":"6114_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","volume":"1754","author":"B Kaminska","year":"2005","unstructured":"Kaminska B (2005) MAPK signaling pathways as molecular targets for anti-inflammatory therapy\u2014from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 1754:253\u2013262. https:\/\/doi.org\/10.1016\/j.bbapap.2005.08.017","journal-title":"Biochim Biophys Acta"},{"key":"6114_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","volume":"12","author":"W Zhang","year":"2002","unstructured":"Zhang W, Liu HT (2002) MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 12:9\u201318. https:\/\/doi.org\/10.1038\/sj.cr.7290105","journal-title":"Cell Res"},{"key":"6114_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10571-022-01191-x","volume":"43","author":"MR Khezri","year":"2022","unstructured":"Khezri MR, Yousefi K, Esmaeili A, Ghasemnejad-Berenji M (2022) The role of ERK1\/2 pathway in the pathophysiology of Alzheimer\u2019s disease: an overview and update on new developments. Cell Mol Neurobiol 43:177\u2013191. https:\/\/doi.org\/10.1007\/s10571-022-01191-x","journal-title":"Cell Mol Neurobiol"},{"key":"6114_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21124471","author":"H Albert-Gasc\u00f3","year":"2020","unstructured":"Albert-Gasc\u00f3 H, Ros-Bernal F, Castillo-G\u00f3mez E, Olucha-Bordonau FE (2020) MAP\/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21124471","journal-title":"Int J Mol Sci"},{"key":"6114_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/105828","volume":"2015","author":"G Verdile","year":"2015","unstructured":"Verdile G, Keane KN, Cruzat VF, Medic S, Sabale M, Rowles J et al (2015) Inflammation and oxidative stress: the molecular connectivity between insulin resistance, obesity, and Alzheimer\u2019s disease. Mediators Inflamm 2015:105828. https:\/\/doi.org\/10.1155\/2015\/105828","journal-title":"Mediators Inflamm"},{"key":"6114_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.expneurol.2017.08.013","volume":"298","author":"CA Peixoto","year":"2017","unstructured":"Peixoto CA, de Oliveira WH, da Ara\u00fajo SM, Nunes AK (2017) AMPK activation: role in the signaling pathways of neuroinflammation and neurodegeneration. Exp Neurol 298:31\u201341. https:\/\/doi.org\/10.1016\/j.expneurol.2017.08.013","journal-title":"Exp Neurol"},{"key":"6114_CR25","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.cellsig.2013.06.007","volume":"25","author":"A Kauppinen","year":"2013","unstructured":"Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A (2013) Antagonistic crosstalk between NF-\u03baB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 25:1939\u20131948. https:\/\/doi.org\/10.1016\/j.cellsig.2013.06.007","journal-title":"Cell Signal"},{"key":"6114_CR26","doi-asserted-by":"publisher","first-page":"1196413","DOI":"10.3389\/fphar.2023.1196413","volume":"14","author":"D Melchiorri","year":"2023","unstructured":"Melchiorri D, Merlo S, Micallef B, Borg J-J, Dr\u00e1fi F (2023) Alzheimer\u2019s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? Front Pharmacol 14:1196413. https:\/\/doi.org\/10.3389\/fphar.2023.1196413","journal-title":"Front Pharmacol"},{"key":"6114_CR27","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1093\/hmg\/ddq142","volume":"19","author":"K Bettens","year":"2010","unstructured":"Bettens K, Sleegers K, Van Broeckhoven C (2010) Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 19:R4-11. https:\/\/doi.org\/10.1093\/hmg\/ddq142","journal-title":"Hum Mol Genet"},{"key":"6114_CR28","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Z Breijyeh","year":"2020","unstructured":"Breijyeh Z, Karaman R (2020) Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules 25:5789. https:\/\/doi.org\/10.3390\/molecules25245789","journal-title":"Molecules"},{"key":"6114_CR29","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.3390\/ijms24076518","volume":"24","author":"B Twarowski","year":"2023","unstructured":"Twarowski B, Herbet M (2023) Inflammatory processes in Alzheimer\u2019s disease-pathomechanism, diagnosis and treatment: a review. Int J Mol Sci 24:6518. https:\/\/doi.org\/10.3390\/ijms24076518","journal-title":"Int J Mol Sci"},{"key":"6114_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K et al (2017) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38:1205\u20131235. https:\/\/doi.org\/10.1038\/aps.2017.28","journal-title":"Acta Pharmacol Sin"},{"key":"6114_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neulet.2019.04.022","volume":"705","author":"NN Naseri","year":"2019","unstructured":"Naseri NN, Wang H, Guo J, Sharma M, Luo W (2019) The complexity of tau in Alzheimer\u2019s disease. Neurosci Lett 705:183\u2013194. https:\/\/doi.org\/10.1016\/j.neulet.2019.04.022","journal-title":"Neurosci Lett"},{"key":"6114_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L (2024) Recent advances in Alzheimer\u2019s disease: mechanisms, clinical trials and new drug development strategies. Sig Transduct Target Ther 9:1\u201335. https:\/\/doi.org\/10.1038\/s41392-024-01911-3","journal-title":"Sig Transduct Target Ther"},{"key":"6114_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70235","volume":"21","author":"Alzheimer\u2019s disease facts and figures","year":"2025","unstructured":"Alzheimer\u2019s disease facts and figures (2025) Alzheimers Dement 21:e70235. https:\/\/doi.org\/10.1002\/alz.70235","journal-title":"Alzheimers Dement"},{"key":"6114_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102481","volume":"101","author":"PT Kamatham","year":"2024","unstructured":"Kamatham PT, Shukla R, Khatri DK, Vora LK (2024) Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: breaking the memory barrier. Ageing Res Rev 101:102481. https:\/\/doi.org\/10.1016\/j.arr.2024.102481","journal-title":"Ageing Res Rev"},{"key":"6114_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216792","volume":"12","author":"MK Sin","year":"2023","unstructured":"Sin MK, Zamrini E, Ahmed A, Nho K, Hajjar I (2023) Anti-amyloid therapy, AD, and ARIA: untangling the role of CAA. J Clin Med 12:6792. https:\/\/doi.org\/10.3390\/jcm12216792","journal-title":"J Clin Med"},{"key":"6114_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016297","author":"F Nonino","year":"2026","unstructured":"Nonino F, Sambati L, Del Giovane C, Baldin E, Bassi MC, De Santis C et al (2026) Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD016297","journal-title":"Cochrane Database Syst Rev"},{"key":"6114_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030558","volume":"20","author":"Y Dong","year":"2019","unstructured":"Dong Y, Li X, Cheng J, Hou L (2019) Drug development for Alzheimer\u2019s disease: microglia induced neuroinflammation as a target? Int J Mol Sci 20:558. https:\/\/doi.org\/10.3390\/ijms20030558","journal-title":"Int J Mol Sci"},{"key":"6114_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM (2016) Alzheimer\u2019s disease: targeting the cholinergic system. Curr Neuropharmacol 14:101\u2013115. https:\/\/doi.org\/10.2174\/1570159X13666150716165726","journal-title":"Curr Neuropharmacol"},{"key":"6114_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"P Francis","year":"1999","unstructured":"Francis P, Palmer A, Snape M, Wilcock G (1999) The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137\u2013147. https:\/\/doi.org\/10.1136\/jnnp.66.2.137","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6114_CR40","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B (2022) The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov 21:306\u2013318. https:\/\/doi.org\/10.1038\/s41573-022-00391-w","journal-title":"Nat Rev Drug Discov"},{"key":"6114_CR41","doi-asserted-by":"publisher","first-page":"ENEURO.0319-23.","DOI":"10.1523\/ENEURO.0319-23.2024","volume":"11","author":"AJ Espay","year":"2024","unstructured":"Espay AJ, Kepp KP, Herrup K (2024) Lecanemab and donanemab as therapies for Alzheimer\u2019s disease: an illustrated perspective on the data. eNeuro 11:ENEURO.0319-23.2024. https:\/\/doi.org\/10.1523\/ENEURO.0319-23.2024","journal-title":"eNeuro"},{"key":"6114_CR42","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/nn.4017","volume":"18","author":"K Herrup","year":"2015","unstructured":"Herrup K (2015) The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18:794\u2013799. https:\/\/doi.org\/10.1038\/nn.4017","journal-title":"Nat Neurosci"},{"key":"6114_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00401-018-1918-8","volume":"136","author":"GP Morris","year":"2018","unstructured":"Morris GP, Clark IA, Vissel B (2018) Questions concerning the role of amyloid-\u03b2 in the definition, aetiology and diagnosis of Alzheimer\u2019s disease. Acta Neuropathol 136:663\u2013689. https:\/\/doi.org\/10.1007\/s00401-018-1918-8","journal-title":"Acta Neuropathol"},{"key":"6114_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2024","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal DR, Boche D et al (2024) Neuroinflammation in Alzheimer disease. Nat Rev Immunol 25:321\u2013352. https:\/\/doi.org\/10.1038\/s41577-024-01104-7","journal-title":"Nat Rev Immunol"},{"key":"6114_CR45","doi-asserted-by":"publisher","unstructured":"Jaturapatporn D, Isaac MG, McCleery J, Tabet N (2012) Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease. Cochrane Database Syst Rev 2012:CD006378. https:\/\/doi.org\/10.1002\/14651858.CD006378.pub2","DOI":"10.1002\/14651858.CD006378.pub2"},{"key":"6114_CR46","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5314","volume":"52","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Zhang X, Zhang R, Wang Z, Gan J, Gao Q et al (2023) Inflammatory signaling pathways in the treatment of Alzheimer\u2019s disease with inhibitors, natural products and metabolites (review). Int J Mol Med 52:111. https:\/\/doi.org\/10.3892\/ijmm.2023.5314","journal-title":"Int J Mol Med"},{"key":"6114_CR47","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10787-020-00751-1","volume":"28","author":"OA Olajide","year":"2020","unstructured":"Olajide OA, Sarker SD (2020) Alzheimer\u2019s disease: natural products as inhibitors of neuroinflammation. Inflammopharmacology 28:1439\u20131455. https:\/\/doi.org\/10.1007\/s10787-020-00751-1","journal-title":"Inflammopharmacology"},{"key":"6114_CR48","doi-asserted-by":"publisher","first-page":"8653","DOI":"10.3390\/ijms21228653","volume":"21","author":"JF Henriques","year":"2020","unstructured":"Henriques JF, Serra D, Dinis TC, Almeida LM (2020) The anti-neuroinflammatory role of anthocyanins and their metabolites for the prevention and treatment of brain disorders. Int J Mol Sci 21:8653. https:\/\/doi.org\/10.3390\/ijms21228653","journal-title":"Int J Mol Sci"},{"key":"6114_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060921","volume":"17","author":"N Leyva-L\u00f3pez","year":"2016","unstructured":"Leyva-L\u00f3pez N, Gutierrez-Grijalva EP, Ambriz-Perez DL, Heredia JB (2016) Flavonoids as cytokine modulators: a possible therapy for inflammation-related diseases. Int J Mol Sci 17:921. https:\/\/doi.org\/10.3390\/ijms17060921","journal-title":"Int J Mol Sci"},{"key":"6114_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3\u201325. https:\/\/doi.org\/10.1016\/S0169-409X(96)00423-1","journal-title":"Adv Drug Deliv Rev"},{"key":"6114_CR51","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1021\/acs.jcim.4c01815","volume":"65","author":"C Jorgensen","year":"2025","unstructured":"Jorgensen C, Linville RM, Galea I, Lambden E, V\u00f6gele M, Chen C et al (2025) Permeability benchmarking: guidelines for comparing in silico, in vitro, and in vivo measurements. J Chem Inf Model 65:1067\u20131084. https:\/\/doi.org\/10.1021\/acs.jcim.4c01815","journal-title":"J Chem Inf Model"},{"key":"6114_CR52","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10545-013-9608-0","volume":"36","author":"NJ Abbott","year":"2013","unstructured":"Abbott NJ (2013) Blood\u2013brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36:437\u2013449. https:\/\/doi.org\/10.1007\/s10545-013-9608-0","journal-title":"J Inherit Metab Dis"},{"key":"6114_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. Neurotherapeutics 2:3\u201314. https:\/\/doi.org\/10.1602\/neurorx.2.1.3","journal-title":"Neurotherapeutics"},{"key":"6114_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101542","volume":"13","author":"F Neumaier","year":"2021","unstructured":"Neumaier F, Zlatopolskiy BD, Neumaier B (2021) Drug penetration into the central nervous system: pharmacokinetic concepts and in vitro model systems. Pharmaceutics 13:1542. https:\/\/doi.org\/10.3390\/pharmaceutics13101542","journal-title":"Pharmaceutics"},{"key":"6114_CR55","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/jps.21580","volume":"98","author":"L Di","year":"2009","unstructured":"Di L, Kerns EH, Bezar IF, Petusky SL, Huang Y (2009) Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB. J Pharm Sci 98:1980\u20131991. https:\/\/doi.org\/10.1002\/jps.21580","journal-title":"J Pharm Sci"},{"key":"6114_CR56","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1002\/ptr.7099","volume":"35","author":"B Chopra","year":"2021","unstructured":"Chopra B, Dhingra AK (2021) Natural products: a lead for drug discovery and development. Phytother Res 35:4660\u20134702. https:\/\/doi.org\/10.1002\/ptr.7099","journal-title":"Phytother Res"},{"key":"6114_CR57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.apsb.2016.06.003","volume":"7","author":"Z Guo","year":"2017","unstructured":"Guo Z (2017) The modification of natural products for medical use. Acta Pharm Sin B 7:119\u2013136. https:\/\/doi.org\/10.1016\/j.apsb.2016.06.003","journal-title":"Acta Pharm Sin B"},{"key":"6114_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1358\/dot.2003.39.1.740206","volume":"39","author":"TM Rees","year":"2003","unstructured":"Rees TM, Brimijoin S (2003) The role of acetylcholinesterase in the pathogenesis of Alzheimer\u2019s disease. Drugs Today 39:75\u201383. https:\/\/doi.org\/10.1358\/dot.2003.39.1.740206","journal-title":"Drugs Today"},{"key":"6114_CR59","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1021\/acschemneuro.1c00537","volume":"13","author":"M Xu","year":"2022","unstructured":"Xu M, Lantz MJ, Nichols RA, Li QX (2022) Anti-neuroinflammatory effects of a semi-synthetic isoorientin-based glycogen synthase kinase-3\u03b2 inhibitor in lipopolysaccharide-activated microglial cells. ACS Chem Neurosci 13:43\u201352. https:\/\/doi.org\/10.1021\/acschemneuro.1c00537","journal-title":"ACS Chem Neurosci"},{"key":"6114_CR60","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s00044-014-1214-7","volume":"24","author":"N Mateeva","year":"2015","unstructured":"Mateeva N, Gangapuram M, Mazzio E, Eyunni S, Soliman KFA, Redda KK (2015) Biological evaluation of synthetic chalcone and flavone derivatives as anti-inflammatory agents. Med Chem Res 24:1672\u20131680. https:\/\/doi.org\/10.1007\/s00044-014-1214-7","journal-title":"Med Chem Res"},{"key":"6114_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106509","volume":"135","author":"SY Chia","year":"2023","unstructured":"Chia SY, Khor BK, Tay YJ, Liew KF, Lee CY (2023) Discovery of blood\u2013brain barrier permeant amine-functionalized aurones as inhibitors of activated microglia. Bioorg Chem 135:106509. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106509","journal-title":"Bioorg Chem"},{"key":"6114_CR62","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.neuint.2015.09.005","volume":"90","author":"N Mrvov\u00e1","year":"2015","unstructured":"Mrvov\u00e1 N, \u0160kand\u00edk M, Kuniakov\u00e1 M, Ra\u010dkov\u00e1 L (2015) Modulation of BV-2 microglia functions by novel quercetin pivaloyl ester. Neurochem Int 90:246\u2013254. https:\/\/doi.org\/10.1016\/j.neuint.2015.09.005","journal-title":"Neurochem Int"},{"key":"6114_CR63","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4062\/biomolther.2018.008","volume":"26","author":"N Kim","year":"2018","unstructured":"Kim N, Yoo H-S, Ju Y-J, Oh MS, Lee K-T, Inn K-S et al (2018) Synthetic 3\u2019,4\u2019-dihydroxyflavone exerts anti-neuroinflammatory effects in BV2 microglia and a mouse model. Biomol Ther (Seoul) 26:210\u2013217. https:\/\/doi.org\/10.4062\/biomolther.2018.008","journal-title":"Biomol Ther (Seoul)"},{"key":"6114_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105951","volume":"77","author":"R Velagapudi","year":"2019","unstructured":"Velagapudi R, Jamshaid F, Lepiarz I, Katola FO, Hemming K, Olajide OA (2019) The tiliroside derivative, 3-O-[(E)-(2-oxo-4-(p-tolyl) but\u20133\u2013en\u20131\u2013yl] kaempferol produced inhibition of neuroinflammation and activation of AMPK and Nrf2\/HO-1 pathways in BV-2 microglia. Int Immunopharmacol 77:105951. https:\/\/doi.org\/10.1016\/j.intimp.2019.105951","journal-title":"Int Immunopharmacol"},{"key":"6114_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109489","volume":"342","author":"M Wang","year":"2021","unstructured":"Wang M, Fang L, Liu T, Chen X, Zheng Y, Zhang Y et al (2021) Discovery of 7-O-1, 2, 3-triazole hesperetin derivatives as multi-target-directed ligands against Alzheimer\u2019s disease. Chem Biol Interact 342:109489. https:\/\/doi.org\/10.1016\/j.cbi.2021.109489","journal-title":"Chem Biol Interact"},{"key":"6114_CR66","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5607\/en.2018.27.5.408","volume":"27","author":"JA Lee","year":"2018","unstructured":"Lee JA, Kim HR, Kim J, Park KD, Kim DJ, Hwang O (2018) The novel neuroprotective compound KMS99220 has an early anti-neuroinflammatory effect via AMPK and HO-1, independent of Nrf2. Exp Neurobiol 27:408\u2013418. https:\/\/doi.org\/10.5607\/en.2018.27.5.408","journal-title":"Exp Neurobiol"},{"key":"6114_CR67","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.bmcl.2018.11.014","volume":"29","author":"Y Yuan","year":"2019","unstructured":"Yuan Y, Subedi L, Lim D, Jung JK, Kim SY, Seo S-Y (2019) Synthesis and anti-neuroinflammatory activity of N-heterocyclic analogs based on natural biphenyl-neolignan honokiol. Bioorg Med Chem Lett 29:329\u2013333. https:\/\/doi.org\/10.1016\/j.bmcl.2018.11.014","journal-title":"Bioorg Med Chem Lett"},{"key":"6114_CR68","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3390\/cells13191652","volume":"13","author":"C Sasia","year":"2024","unstructured":"Sasia C, Borgonetti V, Mancini C, Lori G, Arbiser JL, Taddei ML et al (2024) The neolignan honokiol and its synthetic derivative honokiol hexafluoro reduce neuroinflammation and cellular senescence in microglia cells. Cells 13:1652. https:\/\/doi.org\/10.3390\/cells13191652","journal-title":"Cells"},{"key":"6114_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117092","volume":"282","author":"L Xiong","year":"2025","unstructured":"Xiong L, Zhu H, Liu J, Wang R, Zhong T, Jiang X et al (2025) Design and synthesis of novel derivatives of bisepoxylignans as potent anti-inflammatory agents involves the modulation of the M1\/M2 microglia phenotype via TLR4\/NF-\u03baB signaling pathway. Eur J Med Chem 282:117092. https:\/\/doi.org\/10.1016\/j.ejmech.2024.117092","journal-title":"Eur J Med Chem"},{"key":"6114_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.brainresbull.2015.01.004","volume":"112","author":"HW Lim","year":"2015","unstructured":"Lim HW, Park JI, More SV, Park JY, Kim BW, Jeon SB et al (2015) Anti-neuroinflammatory effects of DPTP, a novel synthetic clovamide derivative in in vitro and in vivo model of neuroinflammation. Brain Res Bull 112:25\u201334. https:\/\/doi.org\/10.1016\/j.brainresbull.2015.01.004","journal-title":"Brain Res Bull"},{"key":"6114_CR71","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1248\/bpb.b17-00303","volume":"40","author":"JY Park","year":"2017","unstructured":"Park JY, Kim BW, Lee HU, Choi DK, Yoon SH (2017) Synthesis of clovamide analogues that inhibit NO production in activated BV-2 microglial cells. Biol Pharm Bull 40:1475\u20131482. https:\/\/doi.org\/10.1248\/bpb.b17-00303","journal-title":"Biol Pharm Bull"},{"key":"6114_CR72","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.bbrc.2020.06.122","volume":"529","author":"A Santarsiero","year":"2020","unstructured":"Santarsiero A, Bochicchio A, Funicello M, Lupattelli P, Choppin S, Colobert F et al (2020) New synthesized polyoxygenated diarylheptanoids suppress lipopolysaccharide-induced neuroinflammation. Biochem Biophys Res Commun 529:1117\u20131123. https:\/\/doi.org\/10.1016\/j.bbrc.2020.06.122","journal-title":"Biochem Biophys Res Commun"},{"key":"6114_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115346","volume":"254","author":"L Lv","year":"2023","unstructured":"Lv L, Maimaitiming M, Huang Y, Yang J, Chen S, Sun Y et al (2023) Discovery of quinazolin-4(3H)-one derivatives as novel AChE inhibitors with anti-inflammatory activities. Eur J Med Chem 254:115346. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115346","journal-title":"Eur J Med Chem"},{"key":"6114_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113713","volume":"224","author":"JJ Tang","year":"2021","unstructured":"Tang JJ, Wang MR, Dong S, Huang LF, He QR, Gao JM (2021) 1,10-seco-eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4\/NF-\u03baB\/MAPK pathways. Eur J Med Chem 224:113713. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113713","journal-title":"Eur J Med Chem"},{"key":"6114_CR75","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.3390\/ijms20205090","volume":"20","author":"S Dhakal","year":"2019","unstructured":"Dhakal S, Kushairi N, Phan CW, Adhikari B, Sabaratnam V, Macreadie I (2019) Dietary polyphenols: a multifactorial strategy to target Alzheimer\u2019s disease. Int J Mol Sci 20:5090. https:\/\/doi.org\/10.3390\/ijms20205090","journal-title":"Int J Mol Sci"},{"key":"6114_CR76","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejphar.2009.06.065","volume":"625","author":"S Mandal","year":"2009","unstructured":"Mandal S, Moudgil M, Mandal SK (2009) Rational drug design. Eur J Pharmacol 625:90\u2013100. https:\/\/doi.org\/10.1016\/j.ejphar.2009.06.065","journal-title":"Eur J Pharmacol"},{"key":"6114_CR77","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD (2015) Molecular docking and structure-based drug design strategies. Molecules 20:13384\u201313421. https:\/\/doi.org\/10.3390\/molecules200713384","journal-title":"Molecules"},{"key":"6114_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/157340911793743547","volume":"7","author":"C Acharya","year":"2011","unstructured":"Acharya C, Coop A, Polli JE, MacKerell AD (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7:10\u201322. https:\/\/doi.org\/10.2174\/157340911793743547","journal-title":"Curr Comput Aided Drug Des"},{"key":"6114_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106378","volume":"133","author":"W Dan","year":"2023","unstructured":"Dan W, Cao Y, Sun Y, Zhang J, Liu J, Gao J et al (2023) Novel N1 or N9 modified \u03b1-carboline analogues as potential ligands in Alzheimer\u2019s disease therapy: synthesis and neurobiological activity evaluation. Bioorg Chem 133:106378. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106378","journal-title":"Bioorg Chem"},{"key":"6114_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127780","volume":"36","author":"SH Yoon","year":"2021","unstructured":"Yoon SH, Lee E, Cho DY, Ko HM, Baek HY, Choi DK et al (2021) Synthesis of 4-(3-oxo-3-phenylpropyl)morpholin-4-ium chloride analogues and their inhibitory activities of nitric oxide production in lipopolysaccharide-induced BV2 cells. Bioorg Med Chem Lett 36:127780. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127780","journal-title":"Bioorg Med Chem Lett"},{"key":"6114_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2025.149804","volume":"1863","author":"J He","year":"2025","unstructured":"He J, Ran M, Tam KY (2025) An orally administered quinolinium molecule mitigates neuropathology of Alzheimer\u2019s disease through modulation of mitochondrial dysfunction and neuroinflammation. Brain Res 1863:149804. https:\/\/doi.org\/10.1016\/j.brainres.2025.149804","journal-title":"Brain Res"},{"key":"6114_CR82","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.bmcl.2013.12.055","volume":"24","author":"YX Yang","year":"2014","unstructured":"Yang YX, Zheng LT, Shi JJ, Gao B, Chen YK, Yang HC et al (2014) Synthesis of 5\u03b1-cholestan-6-one derivatives and their inhibitory activities of NO production in activated microglia: discovery of a novel neuroinflammation inhibitor. Bioorg Med Chem Lett 24:1222\u20131227. https:\/\/doi.org\/10.1016\/j.bmcl.2013.12.055","journal-title":"Bioorg Med Chem Lett"},{"key":"6114_CR83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2019.02.025","volume":"851","author":"MA Alford","year":"2019","unstructured":"Alford MA, Tian Z, Menard F, Klegeris A (2019) Characterization of novel kainic acid analogs as inhibitors of select microglial functions. Eur J Pharmacol 851:25\u201335. https:\/\/doi.org\/10.1016\/j.ejphar.2019.02.025","journal-title":"Eur J Pharmacol"},{"key":"6114_CR84","doi-asserted-by":"publisher","first-page":"13683","DOI":"10.1038\/s41598-017-13996-8","volume":"7","author":"CY Ng","year":"2017","unstructured":"Ng CY, Kannan S, Chen YJ, Tan FC, Ong WY, Go ML et al (2017) A new generation of arachidonic acid analogues as potential neurological agent targeting cytosolic phospholipase A2. Sci Rep 7:13683. https:\/\/doi.org\/10.1038\/s41598-017-13996-8","journal-title":"Sci Rep"},{"key":"6114_CR85","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S (2024) Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther 9:97. https:\/\/doi.org\/10.1038\/s41392-024-01811-6","journal-title":"Signal Transduct Target Ther"},{"key":"6114_CR86","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1002\/med.21699","volume":"41","author":"C Albertini","year":"2021","unstructured":"Albertini C, Salerno A, de Sena Murteira Pinheiro P, Bolognesi ML (2021) From combinations to multitarget-directed ligands: a continuum in Alzheimer\u2019s disease polypharmacology. Med Res Rev 41:2606\u20132633. https:\/\/doi.org\/10.1002\/med.21699","journal-title":"Med Res Rev"},{"key":"6114_CR87","doi-asserted-by":"publisher","first-page":"10581","DOI":"10.1021\/acs.jmedchem.1c00683","volume":"64","author":"X Li","year":"2021","unstructured":"Li X, Li X, Liu F, Li S, Shi D (2021) Rational multitargeted drug design strategy from the perspective of a medicinal chemist. J Med Chem 64:10581\u201310605. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00683","journal-title":"J Med Chem"},{"key":"6114_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101378","volume":"29","author":"S Gunesch","year":"2020","unstructured":"Gunesch S, Hoffmann M, Kiermeier C, Fischer W, Pinto AF, Maurice T et al (2020) 7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo. Redox Biol 29:101378. https:\/\/doi.org\/10.1016\/j.redox.2019.101378","journal-title":"Redox Biol"},{"key":"6114_CR89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejmech.2018.02.063","volume":"149","author":"Y Fang","year":"2018","unstructured":"Fang Y, Xia W, Cheng B, Hua P, Zhou H, Gu Q et al (2018) Design, synthesis, and biological evaluation of compounds with a new scaffold as anti-neuroinflammatory agents for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 149:129\u2013138. https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.063","journal-title":"Eur J Med Chem"},{"key":"6114_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111745","volume":"184","author":"S Sestito","year":"2019","unstructured":"Sestito S, Pruccoli L, Runfola M, Citi V, Martelli A, Saccomanni G et al (2019) Design and synthesis of H2S-donor hybrids: a new treatment for Alzheimer\u2019s disease? Eur J Med Chem 184:111745. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111745","journal-title":"Eur J Med Chem"},{"key":"6114_CR91","doi-asserted-by":"publisher","first-page":"2169682","DOI":"10.1080\/14756366.2023.2169682","volume":"38","author":"H Chen","year":"2023","unstructured":"Chen H, Mi J, Li S, Liu Z, Yang J, Chen R et al (2023) Design, synthesis and evaluation of quinoline-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease. J Enzyme Inhib Med Chem 38:2169682. https:\/\/doi.org\/10.1080\/14756366.2023.2169682","journal-title":"J Enzyme Inhib Med Chem"},{"key":"6114_CR92","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00044-022-03010-w","volume":"32","author":"Y He","year":"2023","unstructured":"He Y, Rao Z, Liu Z, Mi J, Yang J, Zhou Y et al (2023) Design, synthesis and evaluation of salicylic acid-donepezil hybrids as functional agents for the treatment of Alzheimer\u2019s disease. Med Chem Res 32:355\u2013368. https:\/\/doi.org\/10.1007\/s00044-022-03010-w","journal-title":"Med Chem Res"},{"key":"6114_CR93","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1016\/j.bmc.2018.11.015","volume":"26","author":"Q Song","year":"2018","unstructured":"Song Q, Li Y, Cao Z, Liu H, Tian C, Yang Z et al (2018) Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer\u2019s disease. Bioorg Med Chem 26:6115\u20136127. https:\/\/doi.org\/10.1016\/j.bmc.2018.11.015","journal-title":"Bioorg Med Chem"},{"key":"6114_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112997","volume":"212","author":"Z Liu","year":"2021","unstructured":"Liu Z, Zhang B, Xia S, Fang L, Gou S (2021) ROS-responsive and multifunctional anti-Alzheimer prodrugs: tacrine-ibuprofen hybrids via a phenyl boronate linker. Eur J Med Chem 212:112997. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112997","journal-title":"Eur J Med Chem"},{"key":"6114_CR95","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1080\/14756366.2022.207344","volume":"37","author":"G Zhu","year":"2022","unstructured":"Zhu G, Bai P, Wang K, Mi J, Yang J, Hu J et al (2022) Design, synthesis, and evaluation of novel O-alkyl ferulamide derivatives as multifunctional ligands for treating Alzheimer\u2019s disease. J Enzyme Inhib Med Chem 37:1375\u20131388. https:\/\/doi.org\/10.1080\/14756366.2022.207344","journal-title":"J Enzyme Inhib Med Chem"},{"key":"6114_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108551","volume":"161","author":"X Liu","year":"2025","unstructured":"Liu X, Xu J, Yu C, Dai C, Chen J, Zhong J et al (2025) A novel carbamate-based hybrid derivative with anti-neuroinflammatory properties as a selective butyrylcholinesterase inhibitor for Alzheimer\u2019s disease therapy. Bioorg Chem 161:108551. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108551","journal-title":"Bioorg Chem"},{"key":"6114_CR97","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.chembiol.2014.07.015","volume":"21","author":"WP Janzen","year":"2014","unstructured":"Janzen WP (2014) Screening technologies for small molecule discovery: the state of the art. Chem Biol 21:1162\u20131170. https:\/\/doi.org\/10.1016\/j.chembiol.2014.07.015","journal-title":"Chem Biol"},{"key":"6114_CR98","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.drudis.2020.07.024","volume":"25","author":"V Blay","year":"2020","unstructured":"Blay V, Tolani B, Ho SP, Arkin MR (2020) High-throughput screening: today\u2019s biochemical and cell-based approaches. Drug Discov Today 25:1807\u20131821. https:\/\/doi.org\/10.1016\/j.drudis.2020.07.024","journal-title":"Drug Discov Today"},{"key":"6114_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2016.e00132","volume":"2","author":"HN Sun","year":"2016","unstructured":"Sun HN, Shen GN, Jin YZ, Jin Y, Han YH, Feng L et al (2016) 2-cyclohexylamino-5,8-dimethoxy-1,4-naphthoquinone inhibits LPS-induced BV2 microglial activation through MAPK\/NF-kB signaling pathways. Heliyon 2:e00132. https:\/\/doi.org\/10.1016\/j.heliyon.2016.e00132","journal-title":"Heliyon"},{"key":"6114_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.114031","volume":"228","author":"B Ren","year":"2022","unstructured":"Ren B, Guo C, Liu RZ, Bian ZY, Liu RC, Huang LF et al (2022) Imidazolylacetophenone oxime-based multifunctional neuroprotective agents: discovery and structure-activity relationships. Eur J Med Chem 228:114031. https:\/\/doi.org\/10.1016\/j.ejmech.2021.114031","journal-title":"Eur J Med Chem"},{"key":"6114_CR101","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/aps.2015.138","volume":"37","author":"BW Kim","year":"2016","unstructured":"Kim BW, More SV, Yun YS, Ko HM, Kwak J-H, Lee H et al (2016) A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways. Acta Pharmacol Sin 37:334\u2013343. https:\/\/doi.org\/10.1038\/aps.2015.138","journal-title":"Acta Pharmacol Sin"},{"key":"6114_CR102","doi-asserted-by":"publisher","first-page":"12535","DOI":"10.1038\/s41598-017-12082-3","volume":"7","author":"A Venkanna","year":"2017","unstructured":"Venkanna A, Kwon OW, Afzal S, Jang C, Cho KH, Yadav DK et al (2017) Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular similarity search, chemocentric target profiling, and experimental evidence. Sci Rep 7:12535. https:\/\/doi.org\/10.1038\/s41598-017-12082-3","journal-title":"Sci Rep"},{"key":"6114_CR103","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1021\/acschemneuro.0c00328","volume":"11","author":"AD Landgraf","year":"2020","unstructured":"Landgraf AD, Alsegiani AS, Alaqel S, Thanna S, Shah ZA, Sucheck SJ (2020) Neuroprotective and anti-neuroinflammatory properties of ebselen derivatives and their potential to inhibit neurodegeneration. ACS Chem Neurosci 11:3008\u20133016. https:\/\/doi.org\/10.1021\/acschemneuro.0c00328","journal-title":"ACS Chem Neurosci"},{"key":"6114_CR104","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12974-018-1362-7","volume":"15","author":"SW Saliba","year":"2018","unstructured":"Saliba SW, Jauch H, Gargouri B, Keil A, Hurrle T, Volz N et al (2018) Anti-neuroinflammatory effects of GPR55 antagonists in LPS-activated primary microglial cells. J Neuroinflammation 15:322. https:\/\/doi.org\/10.1186\/s12974-018-1362-7","journal-title":"J Neuroinflammation"},{"key":"6114_CR105","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.7150\/thno.96707","volume":"14","author":"HJ Kim","year":"2024","unstructured":"Kim HJ, Kim H, Song J, Hong JY, Lee EH, Londhe AM et al (2024) Highly potent and selective PPAR\u03b4 agonist reverses memory deficits in mouse models of Alzheimer\u2019s disease. Theranostics 14:6088\u20136108. https:\/\/doi.org\/10.7150\/thno.96707","journal-title":"Theranostics"},{"key":"6114_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-017-0399-3","volume":"18","author":"L Subedi","year":"2017","unstructured":"Subedi L, Kwon OW, Pak C, Lee G, Lee K, Kim H et al (2017) N,N-disubstituted azines attenuate LPS-mediated neuroinflammation in microglia and neuronal apoptosis via inhibiting MAPK signaling pathways. BMC Neurosci 18:82. https:\/\/doi.org\/10.1186\/s12868-017-0399-3","journal-title":"BMC Neurosci"},{"key":"6114_CR107","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1248\/bpb.b24-00644","volume":"47","author":"R Nakanishi","year":"2024","unstructured":"Nakanishi R, Kurauchi Y, Kotani S, Hitora-Imamura N, Seki T, Katsuki H (2024) Structurally distinct Nurr1 ligands exhibit different pharmacological characteristics in regulating inflammatory responses of microglial BV-2 cells. Biol Pharm Bull 47:1937\u20131945. https:\/\/doi.org\/10.1248\/bpb.b24-00644","journal-title":"Biol Pharm Bull"},{"key":"6114_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bbi.2022.06.011","volume":"105","author":"AP Young","year":"2022","unstructured":"Young AP, Denovan-Wright EM (2022) Synthetic cannabinoids reduce the inflammatory activity of microglia and subsequently improve neuronal survival in vitro. Brain Behav Immun 105:29\u201343. https:\/\/doi.org\/10.1016\/j.bbi.2022.06.011","journal-title":"Brain Behav Immun"},{"key":"6114_CR109","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s10753-021-01588-8","volume":"45","author":"S-S Zhang","year":"2022","unstructured":"Zhang S-S, Liu M, Liu DN, Yang YL, Du GH, Wang YH (2022) TLR4-IN-C34 inhibits lipopolysaccharide-stimulated inflammatory responses via downregulating TLR4\/MyD88\/NF-\u03baB\/NLRP3 signaling pathway and reducing ROS generation in BV2 cells. Inflammation 45:838\u2013850. https:\/\/doi.org\/10.1007\/s10753-021-01588-8","journal-title":"Inflammation"},{"key":"6114_CR110","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.bmc.2016.03.010","volume":"24","author":"L Li","year":"2016","unstructured":"Li L, Chen M, Jiang FC (2016) Design, synthesis, and evaluation of 2-piperidone derivatives for the inhibition of \u03b2-amyloid aggregation and inflammation mediated neurotoxicity. Bioorg Med Chem 24:1853\u20131865. https:\/\/doi.org\/10.1016\/j.bmc.2016.03.010","journal-title":"Bioorg Med Chem"},{"key":"6114_CR111","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1248\/bpb.b25-00037","volume":"48","author":"K Tomita","year":"2025","unstructured":"Tomita K, Nakashima K-I, Yamaguchi E, Itoh A, Inoue M (2025) Dual anti-inflammatory actions of a novel retinoid X receptor agonist derived from a natural compound in microglial cells. Biol Pharm Bull 48:440\u2013449. https:\/\/doi.org\/10.1248\/bpb.b25-00037","journal-title":"Biol Pharm Bull"},{"key":"6114_CR112","doi-asserted-by":"publisher","unstructured":"L\u00f3pez A, Aparicio N, Pazos MR, M Teresa Grande, Barreda-Manso MA, Benito-Cuesta I et al\u00a0(2018) Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer\u2019s disease. J Neuroinflammation [Internet]. J Neuroinflammation 15. https:\/\/doi.org\/10.1186\/s12974-018-1174-9","DOI":"10.1186\/s12974-018-1174-9"},{"key":"6114_CR113","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.neurobiolaging.2012.06.005","volume":"34","author":"M Solas","year":"2013","unstructured":"Solas M, Francis PT, Franco R, Ramirez MJ (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer\u2019s disease patients. Neurobiol Aging 34:805\u2013808. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.06.005","journal-title":"Neurobiol Aging"},{"key":"6114_CR114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","volume":"153","author":"C Benito","year":"2008","unstructured":"Benito C, Tol\u00f3n RM, Pazos MR, N\u00fa\u00f1ez E, Castillo AI, Romero J (2008) Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153:277\u2013285. https:\/\/doi.org\/10.1038\/sj.bjp.0707505","journal-title":"Br J Pharmacol"},{"key":"6114_CR115","doi-asserted-by":"publisher","first-page":"705","DOI":"10.14336\/AD.2019.0718","volume":"11","author":"SG Jeon","year":"2019","unstructured":"Jeon SG, Yoo A, Chun DW, Hong SB, Chung H, Kim J et al (2019) The critical role of Nurr1 as a mediator and therapeutic target in Alzheimer\u2019s disease-related pathogenesis. Aging Dis 11:705\u2013724. https:\/\/doi.org\/10.14336\/AD.2019.0718","journal-title":"Aging Dis"},{"key":"6114_CR116","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1111\/bph.14668","volume":"176","author":"NF Fitz","year":"2019","unstructured":"Fitz NF, Nam KN, Koldamova R, Lefterov I (2019) Therapeutic targeting of nuclear receptors, liver X and retinoid X receptors, for Alzheimer\u2019s disease. Br J Pharmacol 176:3599\u20133610. https:\/\/doi.org\/10.1111\/bph.14668","journal-title":"Br J Pharmacol"},{"key":"6114_CR117","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1194\/jlr.R075556","volume":"58","author":"M Moutinho","year":"2017","unstructured":"Moutinho M, Landreth GE (2017) Therapeutic potential of nuclear receptor agonists in Alzheimer\u2019s disease. J Lipid Res 58:1937\u20131949. https:\/\/doi.org\/10.1194\/jlr.R075556","journal-title":"J Lipid Res"},{"key":"6114_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A et al (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18:41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"key":"6114_CR119","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbi.2015.07.015","volume":"50","author":"Y Xu","year":"2015","unstructured":"Xu Y, Xu Y, Wang Y, Wang Y, He L, Jiang Z et al (2015) Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKK\u03b2-dependent AMPK activation. Brain Behav Immun 50:298\u2013313. https:\/\/doi.org\/10.1016\/j.bbi.2015.07.015","journal-title":"Brain Behav Immun"},{"key":"6114_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.113674","volume":"171","author":"ZF Wang","year":"2020","unstructured":"Wang ZF, Li J, Ma C, Huang C, Li ZQ (2020) Telmisartan ameliorates A\u03b2 oligomer-induced inflammation via PPAR\u03b3\/PTEN pathway in BV2 microglial cells. Biochem Pharmacol 171:113674. https:\/\/doi.org\/10.1016\/j.bcp.2019.113674","journal-title":"Biochem Pharmacol"},{"key":"6114_CR121","doi-asserted-by":"publisher","unstructured":"Elsaafien K, de Kloet AD, Krause EG, Sumners C (2020) Brain angiotensin type-1 and type-2 receptors in physiological and hypertensive conditions: focus on neuroinflammation. Curr Hypertens Rep Springer US 22:1\u201313. https:\/\/doi.org\/10.1007\/s11906-020-01062-0","DOI":"10.1007\/s11906-020-01062-0"},{"key":"6114_CR122","doi-asserted-by":"publisher","first-page":"943","DOI":"10.3233\/JAD-215231","volume":"85","author":"S Tran","year":"2022","unstructured":"Tran S, Kuruppu S, Rajapakse NW (2022) Chronic renin-angiotensin system activation induced neuroinflammation: common mechanisms underlying hypertension and dementia? J Alzheimers Dis SAGE Publications 85:943\u2013955. https:\/\/doi.org\/10.3233\/JAD-215231","journal-title":"J Alzheimers Dis SAGE Publications"},{"key":"6114_CR123","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2174\/0115672050272577231120060909","volume":"20","author":"S Jin","year":"2023","unstructured":"Jin S, Guan X, Min D (2023) Evidence of clinical efficacy and pharmacological mechanisms of resveratrol in the treatment of Alzheimer\u2019s disease. Curr Alzheimer Res 20:588\u2013602. https:\/\/doi.org\/10.2174\/0115672050272577231120060909","journal-title":"Curr Alzheimer Res"},{"key":"6114_CR124","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/alzrt146","volume":"4","author":"JM Ringman","year":"2012","unstructured":"Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M et al (2012) Oral curcumin for Alzheimer\u2019s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4:43. https:\/\/doi.org\/10.1186\/alzrt146","journal-title":"Alzheimers Res Ther"},{"key":"6114_CR125","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biom10010059","volume":"10","author":"H Khan","year":"2020","unstructured":"Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK (2020) Neuroprotective effects of quercetin in Alzheimer\u2019s disease. Biomolecules 10:59. https:\/\/doi.org\/10.3390\/biom10010059","journal-title":"Biomolecules"},{"key":"6114_CR126","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.2010.05842.x","volume":"1215","author":"T Walle","year":"2011","unstructured":"Walle T (2011) Bioavailability of resveratrol. Ann N Y Acad Sci 1215:9\u201315. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05842.x","journal-title":"Ann N Y Acad Sci"},{"key":"6114_CR127","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3389\/fncel.2018.00323","volume":"12","author":"Z Szepesi","year":"2018","unstructured":"Szepesi Z, Manouchehrian O, Bachiller S, Deierborg T (2018) Bidirectional microglia\u2013neuron communication in health and disease. Front Cell Neurosci 12:323. https:\/\/doi.org\/10.3389\/fncel.2018.00323","journal-title":"Front Cell Neurosci"},{"key":"6114_CR128","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70061","volume":"137","author":"JH Magnussen","year":"2025","unstructured":"Magnussen JH (2025) Therapeutic targeting of the \u03b17 nicotinic receptor: challenges and prospects for cognitive improvement in Alzheimer\u2019s and schizophrenia. Basic Clin Pharmacol Toxicol 137:e70061. https:\/\/doi.org\/10.1111\/bcpt.70061","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6114_CR129","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-024-00397-x","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Tan Y, Zhang Z, Yi M, Zhu L, Peng W (2024) The interaction between ageing and Alzheimer\u2019s disease: insights from the hallmarks of ageing. Transl Neurodegener 13:7. https:\/\/doi.org\/10.1186\/s40035-024-00397-x","journal-title":"Transl Neurodegener"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06114-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06114-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T08:25:18Z","timestamp":1786177518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06114-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":129,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6114"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06114-1","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"819"}}